These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 12629413)

  • 21. The synthetic estrogen diethylstilbestrol (DES) inhibits the telomerase activity and gene expression of prostate cancer cells.
    Geier R; Adler S; Rashid G; Klein A
    Prostate; 2010 Sep; 70(12):1307-12. PubMed ID: 20623632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Androgens repress Bcl-2 expression via activation of the retinoblastoma (RB) protein in prostate cancer cells.
    Huang H; Zegarra-Moro OL; Benson D; Tindall DJ
    Oncogene; 2004 Mar; 23(12):2161-76. PubMed ID: 14676836
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Possible role of adaptive mutation in resistance to antiandrogen in prostate cancer cells.
    Hara T; Kouno J; Nakamura K; Kusaka M; Yamaoka M
    Prostate; 2005 Nov; 65(3):268-75. PubMed ID: 16015592
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of telomerase activity and secretion of prostate specific antigen by silibinin in prostate cancer cells.
    Thelen P; Wuttke W; Jarry H; Grzmil M; Ringert RH
    J Urol; 2004 May; 171(5):1934-8. PubMed ID: 15076315
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Silibinin down-regulates prostate epithelium-derived Ets transcription factor in LNCaP prostate cancer cells.
    Thelen P; Jarry H; Ringert RH; Wuttke W
    Planta Med; 2004 May; 70(5):397-400. PubMed ID: 15124082
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Androgens induce resistance to bcl-2-mediated apoptosis in LNCaP prostate cancer cells.
    Berchem GJ; Bosseler M; Sugars LY; Voeller HJ; Zeitlin S; Gelmann EP
    Cancer Res; 1995 Feb; 55(4):735-8. PubMed ID: 7850782
    [TBL] [Abstract][Full Text] [Related]  

  • 27. YB-1 is upregulated during prostate cancer tumor progression and increases P-glycoprotein activity.
    Giménez-Bonafé P; Fedoruk MN; Whitmore TG; Akbari M; Ralph JL; Ettinger S; Gleave ME; Nelson CC
    Prostate; 2004 May; 59(3):337-49. PubMed ID: 15042610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression profiling of androgen-dependent and -independent LNCaP cells: EGF versus androgen signalling.
    Oosterhoff JK; Grootegoed JA; Blok LJ
    Endocr Relat Cancer; 2005 Mar; 12(1):135-48. PubMed ID: 15788645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Regulation of prostate-specific antigen by activin A in prostate cancer LNCaP cells.
    Fujii Y; Kawakami S; Okada Y; Kageyama Y; Kihara K
    Am J Physiol Endocrinol Metab; 2004 Jun; 286(6):E927-31. PubMed ID: 14761877
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Regulation of Bcl-2 during androgen-unresponsive progression of prostate cancer.
    Rothermund CA; Kondrikov D; Lin MF; Vishwanatha JK
    Prostate Cancer Prostatic Dis; 2002; 5(3):236-45. PubMed ID: 12496988
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alteration of gene expression in response to bone morphogenetic protein-2 in androgen-dependent human prostate cancer LNCaP cells.
    Kumagai T; Tomari K; Shimizu T; Takeda K
    Int J Mol Med; 2006 Feb; 17(2):285-91. PubMed ID: 16391828
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Interleukin-4 stimulates androgen-independent growth in LNCaP human prostate cancer cells.
    Lee SO; Pinder E; Chun JY; Lou W; Sun M; Gao AC
    Prostate; 2008 Jan; 68(1):85-91. PubMed ID: 18008330
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Effect of dihydrotestosterone on the transcriptions and expressions of Smad3 and Smad4 in LNCaP cell line].
    Gu RG; Zhou CW; Ma QZ
    Zhonghua Nan Ke Xue; 2006 Mar; 12(3):211-4. PubMed ID: 16597033
    [TBL] [Abstract][Full Text] [Related]  

  • 34. T-cell receptor gamma chain alternate reading frame protein (TARP) expression in prostate cancer cells leads to an increased growth rate and induction of caveolins and amphiregulin.
    Wolfgang CD; Essand M; Lee B; Pastan I
    Cancer Res; 2001 Nov; 61(22):8122-6. PubMed ID: 11719440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dihydrotestosterone (DHT) modulates the ability of NSAIDs to induce apoptosis of prostate cancer cells.
    Andrews P; Krygier S; Djakiew D
    Cancer Chemother Pharmacol; 2002 Mar; 49(3):179-86. PubMed ID: 11935209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Androgen signaling and post-transcriptional downregulation of Bcl-2 in androgen-unresponsive prostate cancer.
    Rothermund CA; Gopalakrishnan VK; Vishwanatha JK
    Prostate Cancer Prostatic Dis; 2004; 7(2):158-64. PubMed ID: 15124003
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prostate specific antigen gene expression in androgen insensitive prostate carcinoma subculture cell line.
    Tsui KH; Feng TH; Chung LC; Chao CH; Chang PL; Juang HH
    Anticancer Res; 2008; 28(4A):1969-76. PubMed ID: 18649734
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Suppression of LNCaP prostate cancer xenograft tumors by a prostate-specific protein tyrosine phosphatase, prostatic acid phosphatase.
    Igawa T; Lin FF; Rao P; Lin MF
    Prostate; 2003 Jun; 55(4):247-58. PubMed ID: 12712404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Functional localization and competition between the androgen receptor and T-cell factor for nuclear beta-catenin: a means for inhibition of the Tcf signaling axis.
    Mulholland DJ; Read JT; Rennie PS; Cox ME; Nelson CC
    Oncogene; 2003 Aug; 22(36):5602-13. PubMed ID: 12944908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells.
    Arnold JT; Le H; McFann KK; Blackman MR
    Am J Physiol Endocrinol Metab; 2005 Mar; 288(3):E573-84. PubMed ID: 15536203
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.